214 related articles for article (PubMed ID: 33064889)
1. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
[TBL] [Abstract][Full Text] [Related]
5. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
Ren QX; Li XG; Mu JS; Bi JF; Du CH; Wang YH; Zhu H; Lv P; Zhao QG
J Pharm Sci; 2019 Dec; 108(12):3923-3931. PubMed ID: 31562869
[TBL] [Abstract][Full Text] [Related]
9. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
[TBL] [Abstract][Full Text] [Related]
12. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
[TBL] [Abstract][Full Text] [Related]
14. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
16. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: A population pharmacokinetic approach.
Tang D; Song BL; Yan M; Zou JJ; Zhang M; Zhou HY; Wang F; Xiao YW; Xu P; Zhang BK; Chen XJ; Xiang DX; Linh Banh H
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):34-43. PubMed ID: 30715804
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization.
Chantharit P; Tantasawat M; Kasai H; Tanigawara Y
Ther Drug Monit; 2020 Dec; 42(6):872-879. PubMed ID: 32947557
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis.
Gustot T; Ter Heine R; Brauns E; Cotton F; Jacobs F; Brüggemann RJ
J Antimicrob Chemother; 2018 Sep; 73(9):2493-2496. PubMed ID: 29860319
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
